Drug profile · INN
bictegravir + emtricitabine + tenofovir alafenamide
BIKTARVY
bictegravir + emtricitabine + tenofovir alafenamide (BIKTARVY) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
Drug details — bictegravir + emtricitabine + tenofovir alafenamide
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.81
Quick answer
bictegravir + emtricitabine + tenofovir alafenamide (BIKTARVY) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Recent coverage
KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
This page should frame the KRX English IR reference as a company disclosure/investor-relations document and give readers a concise way to navigate its purpose and likely themes. Keep the summary factual and avoid adding performance or product claims not present in the source.
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
FDA approves Merck's IDVYNSO (doravirine/islatravir), the first non-INSTI, tenofovir-free two-drug HIV regimen showing non-inferior efficacy to BIKTARVY.
Pipeline programs
Frequently asked questions
What is bictegravir + emtricitabine + tenofovir alafenamide?
bictegravir + emtricitabine + tenofovir alafenamide (BIKTARVY) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
What is the brand name for bictegravir + emtricitabine + tenofovir alafenamide?
BIKTARVY is a marketed brand name for bictegravir + emtricitabine + tenofovir alafenamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.